Boston Scientific Leads The Charge For Stem Cell Alliances With Osiris Stake
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's investment in stem cell therapy developer Osiris Therapeutics may signal a wave of device/biotech collaborations related to delivery techniques for stem cell treatments